



ASX ANNOUNCEMENT

11 October 2017

Van Leeuwenhoeck Institute Updates Cynata Research Coverage

Melbourne, Australia; 11 October 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that Van Leeuwenhoeck Institute has updated equity analyst coverage with the release of a new report on Cynata. Van Leeuwenhoeck Institute provides expert independent equity research of innovative biotech companies in Europe, North America, Australia and emerging markets for institutional investors and professional investors throughout the US and Europe.

The full Van Leeuwenhoeck research report can be viewed on Cynata's website at www.cynata.com.

Ends

CONTACTS: Dr Ross Macdonald, CEO, 0412 119343, ross.macdonald@cynata.com
Daniel Paproth, Australia Media Contact, 0421 858 982 , daniel.paproth@mcpartners.com.au
Laura Bagby, U.S. Media Contact, 312-448-8098, lbagby@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus' novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata's unique "off-the-shelf" Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.